Our Pricing

Wegovy Side Effects vs Mounjaro: Real UK Weight Loss Data

When comparing wegovy side effects vs mounjaro uk data, understanding the tolerability profile of each medication is essential for making an informed treatment choice. At Cured Pharmacy, our UK clinical team has supported thousands of patients through both semaglutide (Wegovy) and tirzepatide (Mounjaro) treatment journeys, and we've compiled real-world insights alongside published trial data to help you understand what to expect from each medication.

Wegovy Side Effects vs Mounjaro: Clinical Trial Data

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are GLP-1 receptor agonists licensed by the MHRA for weight management in the UK, but their side effect profiles differ in frequency and severity. In the STEP 1 trial, 74% of Wegovy patients reported gastrointestinal adverse events, with nausea affecting 44% of participants [1]. By comparison, the SURMOUNT-1 trial showed that 81% of Mounjaro patients experienced gastrointestinal side effects, though the incidence varied significantly by dose [2].

Nausea is the most commonly reported side effect for both medications, typically peaking during dose escalation phases. In clinical trials, moderate to severe nausea occurred in approximately 20% of Wegovy patients versus 18-25% of Mounjaro patients depending on the prescribed dose [1][2]. The key difference lies in duration: Wegovy's once-weekly 2.4mg maintenance dose produces more consistent GLP-1 activation, whilst Mounjaro's dual GIP/GLP-1 mechanism may cause more pronounced initial effects that often diminish after 4-6 weeks.

Discontinuation rates due to adverse events provide insight into real-world tolerability. In the STEP trials, 4.5% of Wegovy patients discontinued treatment due to gastrointestinal side effects [1]. The SURMOUNT trials reported discontinuation rates of 4.3-6.2% for Mounjaro, with higher doses showing slightly elevated rates [2]. These figures suggest comparable overall tolerability between the two medications when prescribed appropriately.

Common Side Effects: What UK Patients Experience

Based on UK patient feedback and clinical experience at Cured Pharmacy, the most frequently reported side effects for both medications include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort. These gastrointestinal effects occur because GLP-1 receptor agonists slow gastric emptying and reduce appetite through central nervous system pathways [3].

Wegovy patients often describe a gradual onset of nausea that intensifies during the first 48 hours after injection, then subsides over 3-4 days. Many UK patients report that eating smaller, more frequent meals and avoiding high-fat foods significantly reduces symptom severity. Mounjaro users frequently experience similar patterns, though some report more pronounced appetite suppression and earlier satiety, which can make maintaining adequate nutrition challenging during the first month.

Less common but notable side effects include injection site reactions (affecting 5-8% of patients with both medications), fatigue during initial weeks, and occasional headaches [1][2]. A small percentage of patients report hair thinning after 3-6 months of treatment, likely related to rapid weight loss rather than direct medication effects. UK prescribers typically monitor these symptoms during follow-up consultations and adjust dosing schedules if side effects become problematic.

Managing Side Effects Effectively

Our UK clinical team recommends several evidence-based strategies to minimise side effects with both Wegovy and Mounjaro. Start with the lowest prescribed dose and follow the recommended titration schedule without rushing to higher doses. Stay well-hydrated, aiming for 2-3 litres of water daily, and consider ginger tea or over-the-counter anti-nausea medications if symptoms persist. Injecting before bedtime may help patients sleep through peak nausea periods, though this approach doesn't work for everyone.

If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis (intense upper abdominal pain radiating to the back), contact your prescriber immediately. These symptoms, whilst rare, require prompt medical assessment. Subject to prescriber approval, dose adjustments or temporary treatment pauses may be necessary to ensure safe, sustainable weight loss.

Wegovy or Mounjaro: Which Has Fewer Side Effects?

The question of which medication produces fewer side effects doesn't have a straightforward answer, as individual responses vary considerably. Wegovy's single-pathway GLP-1 mechanism may offer slightly better gastrointestinal tolerability for some patients, particularly those sensitive to rapid changes in gut motility. However, Mounjaro's dual GIP/GLP-1 action produces superior weight loss outcomes in head-to-head comparisons, which may justify slightly higher initial side effect rates for patients prioritising maximum efficacy [4].

UK prescribers typically consider several factors when recommending one medication over the other: previous experience with GLP-1 medications, baseline gastrointestinal sensitivity, weight loss goals, and budget considerations. Patients who struggled with nausea on Saxenda (liraglutide) may find Wegovy more tolerable due to its once-weekly dosing, whilst those who tolerated Saxenda well often transition successfully to Mounjaro's higher-potency formulation.

At Cured Pharmacy, Wegovy starts from £135.00 and Mounjaro from £135.00, with all pricing confirmed before your free online consultation. Your UK prescriber will assess your medical history, current medications, and treatment preferences to recommend the most appropriate option based on both efficacy and tolerability considerations.

Real UK Weight Loss Results: Wegovy vs Mounjaro

Clinical trial data provides the most reliable evidence for comparing weight loss outcomes between these medications. In the STEP 1 trial, Wegovy patients achieved an average 14.9% body weight reduction over 68 weeks [1]. The SURMOUNT-1 trial demonstrated that Mounjaro patients lost an average of 20.9% of their body weight over 72 weeks on the highest dose, representing a significant advantage [2].

Real-world UK data from our clinical team at Cured Pharmacy aligns closely with published trial results. Patients who complete the full Wegovy titration schedule and maintain treatment for 12 months typically lose 12-16% of their starting weight, subject to adherence with dietary modifications and increased physical activity. Mounjaro patients following the same lifestyle interventions often achieve 16-22% weight loss over similar timeframes, though individual results vary based on starting BMI, metabolic factors, and treatment adherence.

It's important to note that maximum weight loss typically occurs between months 9-12 of treatment, with most patients reaching a plateau thereafter [1][2]. Both medications require ongoing use to maintain weight loss, as discontinuation often leads to gradual weight regain. UK prescribers emphasise that these medications work best as part of a comprehensive weight management programme including dietary changes, increased physical activity, and behavioural support.

Factors Influencing Weight Loss Success

Several factors influence how much weight you'll lose on either medication. Starting BMI plays a significant role, with patients who have higher baseline weights often achieving greater absolute weight loss but similar percentage reductions. Adherence to prescribed dosing schedules is critical, as missed injections can reduce efficacy and increase side effects when treatment resumes. Dietary composition matters too: patients who reduce processed carbohydrates and increase protein intake typically report better satiety and more sustainable results.

Age and metabolic health also affect outcomes. Younger patients and those without insulin resistance often respond more robustly to GLP-1 therapies. Previous weight loss attempts don't predict medication response, meaning patients who struggled with traditional diet and exercise programmes can still achieve significant results with pharmacotherapy. Your UK prescriber will consider all these factors during your clinical assessment to set realistic expectations and optimise your treatment plan.

Serious Side Effects and Safety Considerations

Whilst most side effects of Wegovy and Mounjaro are mild to moderate gastrointestinal symptoms, both medications carry rare but serious risks that UK prescribers carefully screen for. Acute pancreatitis has been reported in approximately 0.2% of patients in clinical trials, presenting as severe, persistent abdominal pain that may radiate to the back [1][2]. If you experience these symptoms, stop your medication and seek immediate medical attention.

Both medications carry a boxed warning regarding thyroid C-cell tumours, based on rodent studies showing increased risk of medullary thyroid carcinoma. Whilst this hasn't been confirmed in humans, UK prescribers won't prescribe these medications to patients with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 [3]. Gallbladder disease, including cholecystitis and cholelithiasis, occurs more frequently in patients losing weight rapidly, affecting approximately 1-2% of treated patients [1][2].

Hypoglycaemia is uncommon in patients using these medications for weight loss alone, but risk increases if you're also taking insulin or sulfonylureas for diabetes. UK prescribers will review all your current medications during consultation to identify potential interactions. Kidney function should be monitored if you experience severe vomiting or diarrhoea leading to dehydration, as this can temporarily impair renal function. These safety considerations underscore why prescription assessment by a UK-registered clinician is mandatory before starting treatment.

Getting Started with Wegovy or Mounjaro at Cured Pharmacy

Starting treatment at Cured Pharmacy is straightforward and fully compliant with UK pharmaceutical regulations. Complete our free online consultation, which takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications. A UK-registered prescriber reviews your assessment, typically within 24 hours, and determines whether Wegovy, Mounjaro, or an alternative treatment is most appropriate for your circumstances.

If approved, we'll dispense your medication from our UK-registered pharmacy (GPhC Registration Number 9012511) with discreet packaging and next-day delivery options. You'll receive detailed administration instructions, side effect management guidance, and access to ongoing clinical support from our team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). We provide transparent upfront pricing with no hidden consultation fees, and our lowest price guarantee ensures you're getting competitive UK rates.

Both Wegovy and Mounjaro require gradual dose escalation over several months to minimise side effects and optimise tolerability. Your prescriber will outline the specific titration schedule during your consultation, and we'll coordinate prescription renewals to ensure uninterrupted treatment. Whether you choose Wegovy side effects vs mounjaro uk based on tolerability, efficacy, or cost considerations, our clinical team provides personalised support throughout your weight loss journey.

Why Choose Cured Pharmacy for Weight Loss Treatment

Cured Pharmacy combines clinical expertise with genuine UK-licensed medications and transparent pricing. Unlike some online providers, we show exact prices before consultation, never add hidden fees, and guarantee you're receiving authentic MHRA-approved medications. Our UK clinical team has extensive experience managing GLP-1 therapies and provides responsive support if you experience side effects or have questions during treatment.

We stock the full range of UK-licensed weight loss medications, including Wegovy from £135.00, Mounjaro from £135.00, Saxenda from £135.00, and oral options like Orlistat from £135.00. This comprehensive formulary means your prescriber can recommend the optimal treatment based on your individual circumstances rather than limited stock availability. Start your free consultation today to discover which medication offers the best balance of efficacy and tolerability for your weight loss goals.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
4. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., & SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modifications, and lifestyle factors.